AstraZeneca PLC’s anti-interleukin-13 (IL-13) human monoclonal antibody tralokinumab has failed in two further Phase III studies (STRATOS 2 and TROPOS), leaving the company now banking on benralizumab to help offset generic pressure to its asthma franchise.
AstraZeneca has yet to call time on tralokinumab; it said it was still analysing the results but would provide an...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)